Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.
Peter J. Goebell
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer; Roche
Ulrich Kube
No relevant relationships to disclose
Michael Staehler
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Christian Doehn
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Thomas Steiner
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Manfred Kindler
No relevant relationships to disclose
Edwin Herrmann
No relevant relationships to disclose
Jan Janssen
No relevant relationships to disclose
Steffen Weikert
Consultant or Advisory Role - Bayer; Genentech; MOLOGEN; Novartis; Pfizer
Other Remuneration - Bayer; GlaxoSmithKline; Novartis; Pfizer
Michael Thomas Scheffler
No relevant relationships to disclose
Joerg Schmitz
No relevant relationships to disclose
Friedrich Overkamp
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Gernot Guderian
Employment or Leadership Position - Novartis
Michael Albrecht
Employment or Leadership Position - Novartis
Lothar Bergmann
Consultant or Advisory Role - Novartis
Honoraria - Novartis